NCT04802863View on ClinicalTrials.gov

Intrapulmonary Pharmacokinetics of XNW4107, Imipenem and Cilastatin in Healthy Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

21

Participants

Timeline

Start Date

March 25, 2021

Primary Completion Date

May 15, 2021

Study Completion Date

September 30, 2021

Conditions
Bacterial Infections
Interventions
DRUG

XNW4107, Imipenem/Cilastatin

Five doses of 250 mg XNW4107 in combination with 500 mg imipenem/500 mg cilastatin

Trial Locations (1)

85032

Pulmonary Associates PA, Phoenix

Sponsors
All Listed Sponsors
lead

Evopoint Biosciences Inc.

INDUSTRY